Fig. 1

The mutation of NTRK gene family as an independent predictive biomarker in pan-cancer immunotherapy. (A) Kaplan–Meier survival analysis stratified by NTRK mutation status in 1610 cancer patients with 10 types of tumors treated with ICIs in the discovery cohort. (B) Association between NTRK mutation and OS in 2278 patients with 7 types of tumors treated with ICIs in the validation cohort. (C-E) Comparison of OS (C), ORR (D), and PFS (E) between patients with NTRK mutation and patients with NTRK non-mutation in 3888 patients with 12 tumor types treated with ICIs. (F-G) Univariate (F) and multivariate (H) Cox analysis of the association between NTRK mutation and OS in 3888 patients with 12 tumor types treated with ICIs. (H) Nomogram to predict the 12- and 24-month survival. It can calculate overall survival from the date of immunotherapy start. To use, locate ‘age’ axis and draw a line up to the ‘point’ axis to get a score associated with age, repeat for the other features to get their scores. Sum all scores and locate it on the ‘total point’ axis, draw a line to ’12-month survival’ axis to get the 12-month OS probability. (I-J) Based on the optimal cutoff value derived from nomogram, low-score was associated with favorable OS in both discovery cohort (I) and validation cohort (J). CI, confidence interval; CR, complete response; HR, hazard ratio; ICI, immune checkpoint inhibitor; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TMB, tumor mutation burden